MassMutual Private Wealth & Trust FSB Trims Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

MassMutual Private Wealth & Trust FSB lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 41.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,087 shares of the medical research company’s stock after selling 755 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Charles River Laboratories International were worth $201,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. American Century Companies Inc. lifted its position in Charles River Laboratories International by 4.6% during the second quarter. American Century Companies Inc. now owns 6,556 shares of the medical research company’s stock valued at $1,354,000 after buying an additional 291 shares during the period. Mercer Global Advisors Inc. ADV boosted its stake in Charles River Laboratories International by 74.5% during the second quarter. Mercer Global Advisors Inc. ADV now owns 4,031 shares of the medical research company’s stock worth $833,000 after acquiring an additional 1,721 shares in the last quarter. Amalgamated Bank grew its holdings in Charles River Laboratories International by 21.7% in the second quarter. Amalgamated Bank now owns 13,036 shares of the medical research company’s stock worth $2,693,000 after purchasing an additional 2,323 shares during the period. Canada Pension Plan Investment Board bought a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $124,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Charles River Laboratories International by 6.2% during the second quarter. ProShare Advisors LLC now owns 9,975 shares of the medical research company’s stock valued at $2,061,000 after purchasing an additional 583 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Down 0.9 %

Shares of NYSE:CRL opened at $168.27 on Thursday. The stock’s 50-day simple moving average is $187.81 and its two-hundred day simple moving average is $197.72. The stock has a market capitalization of $8.61 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 5.75 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52-week low of $160.85 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period in the previous year, the business posted $2.72 earnings per share. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. Analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on CRL. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Redburn Atlantic initiated coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target for the company. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Evercore ISI raised their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. Finally, UBS Group reiterated a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $209.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).